Autres langues Indivior Pharmaceuticals, Inc. Xetra

Actions

E7P

US45579U1097

Produits pharmaceutiques

Temps réel estimé Tradegate 15:49:44 18/09/2026			Varia. 5j.	Varia. 1 janv.
30,70 ^EUR	-1,60%		+5,41%	-

17/09	Indivior Pharmaceuticals, Inc. annonce un dividende exceptionnel en numéraire, payable vers le 6 novembre 2026	CI
17/09	Indivior fixe un dividende exceptionnel de 8,13 $ par action sous réserve de la finalisation de la fusion avec Supernus	MT

Autres langues

17/09	Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend, Payable on or About November 6, 2026
17/09	Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger
16/09	Indivior Terminates Supply Agreement With Reckitt Benckiser
03/08	Indivior Pharmaceuticals, Inc. Enters into Senior Secured Term Loan Facility
03/08	Indivior Pharmaceuticals, Inc. Proposes Special Cash Dividend
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Timothy C. Dec as Chief Financial Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026
03/08	Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Member of the Board of the Supernus, Inc
03/08	Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	Tranche Update on Indivior Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 26, 2026.
03/08	Supernus, Indivior merge to strengthen neuroscience drug portfolio
03/08	Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
03/08	Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger
03/08	Indivior Pharmaceuticals Q2 Non-GAAP Earnings, Revenue Rise; 2026 Sales Outlook Upgraded
03/08	(INDV) Indivior Expects 2026 Net Revenue Range $1.30B - $1.37B, vs. FactSet Est of $1.26B
03/08	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q2 Revenue $343.0M, vs. FactSet Est of $307.6M
03/08	Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.15 per Share, vs. FactSet Est of $0.89
30/07	Indivior Pharmaceuticals : Half a Million Reasons to Hope
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index
29/06	Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Defensive Index
10/06	Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing
21/05	Indivior Pharmaceuticals - New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
20/05	Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine